Searched for
PLASMID
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Tech millionaire claims to have slowed down aging by DNA editing. Will this technology help humans live forever?Millionaire Bryan Johnson visited a remote island to extend his life. He spent $20,000 for a treatment that would keep him young forever.
- Zydus Cadila starts supply of Covid 19 vaccine to govtThe Ahmedabad-based drugmaker has also entered into a definitive agreement with Shilpa Medicare Ltd, a contract manufacturing organisation,...
- Production ramp up delayed Zydus Cadila’s vaccine launch, roll out likely soonZydus had received an order from the government to supply 10 million doses of ZyCoV-D, the world's first plasmid DNA vaccine, at ₹265 per d...
- Cadila's Covid vax to be introduced in 7 states firstThe Indian government will initially introduce Cadila Healthcare's Covid-19 vaccine ZyCoV-D in seven states, including Maharashtra and West...
- Zydus Cadila's Covid vaccine to be administered only to adults as of now: SourcesZydus Cadila's COVID-19 vaccine ZyCov-D, which has been cleared by India's drug regulator for those aged 12 years and above, will only be a...
- NTAGI to soon come out with guidelines on vaccinating kidsZyCoV-D is the first DNA plasmid vaccine in the world , developed indigenously by the company against the Covid-19 virus.
- Zydus Cadila to supply 1 crore doses of ZyCoV-D to govt at Rs 265/doseZydus Cadila will supply 1 crore doses of its vaccine ZyCoV-D, the world's first plasmid DNA vaccine to the government of India at Rs 265 p...
- Zydus to seek emergency nod for Covid vaccine soonThe company is expected to present phase III data for ZyCoV-D--a plasmid DNA vaccine—to the country’s drug regulatory authority by next wee...
- Zydus Cadila likely to seek emergency use authorisation for its Covid vaccine next weekPharmaceutical major Zydus Cadila has told the Centre that it could apply for emergency use authorisation (EUA) for ZyCoV-D vaccine in the ...
- Cadila Healthcare Working on Needle-free, 2-Dose VaccineThe drug company is conducting phase-3 trials with over 20,000 participants to test whether its three-dose vaccine ZyCoV-D prevents virolog...
- Zydus Cadila to apply for Phase-3 trials in December, hopes to launch vaccine by MarchThe Ahmedabad-based drug maker will submit the results of its phase-2 trials next week, which "will ascertain the safety, dose and efficacy...
- Cadila Healthcare Q2 results: Net profit jumps over four-fold to Rs 473.4 crConsolidated total revenue from operations of the company stood at Rs 3,820 crore for the quarter under consideration. It was Rs 3,366.6 cr...
- Cadila, one of India's two Covid vaccine makers, is going in for a huge capacity boostWhile Cadila’s plasmid DNA candidate doesn’t use an infectious agent like others, and instead introduces the DNA sequence encoding the anti...
- India seems to be getting closer to an antidote, even as the coronavirus situation worsensThis week India overtook the US in daily addition of new COVID-19 cases. It is worrying. The World Health Organization says that the infect...
- Zydus Cadila begins human trials of its COVID-19 vaccine, aims for an early 2021 launchThe company said in the preclinical stage the vaccine was found to be safe, immunogenic and well-tolerated. It was also able to produce neu...
- India's Zydus begins human trials for potential COVID-19 vaccineZyCoV-D, its plasmid DNA vaccine,found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies.In the human trials,...
- 'Superbug from India resistant to all available antibiotics'The infection was caused by carbapenem-resistant Enterobacteriaceae (CRE), a multidrug-resistant organism associated with high mortality.
- Common bacteria may become antibiotic-resistant superbugsThe researchers studied a family of bacteria called Enterobacteriaceae, which includes E coli, Klebsiella pneumoniae and Enterobacter.
Load More
